| Course | MBAX 6332 Health Policy and Systems Thinking |
|---|---|
| Week | Week 3 |
| Paper type | Evidence review |
| Length | About 860 words, 6 pages |
| Format | APA 7 student paper |
| School | Walden University |
| Program | Master of Business Administration (MBA) |
| Updated | October 2026 |
Free sample paper for MBAX 6332 Week 3
Who Counts Hospital-Acquired Conditions, How and What Each Count Misses: An Evidence Review of Four Sources Before Any Figure Enters the Argument About Medicare's Penalty Program
Student Name
Walden University
MBAX 6332: Health Policy and Systems Thinking
Instructor Name
Month Day, Year
Who Counts Hospital-Acquired Conditions, How and What Each Count Misses: An Evidence Review of Four Sources Before Any Figure Enters the Argument About Medicare's Penalty Program
Purpose
Arguments about the Hospital-Acquired Condition Reduction Program often begin with a number: infection rates have fallen, penalized hospitals did not improve, safety-net hospitals are penalized more. Each number comes from a source that counts something particular, in a particular way, with particular gaps. This review asks who publishes the evidence on hospital-acquired conditions, how each source counts and what each leaves out, before the course uses any figure in its argument. It is written from the perspective of a quality analyst at a composite regional hospital who prepares the data some of these sources use. Bardach and Patashnik (2020) advise policy analysts to assemble evidence by first understanding how it was produced, since a figure's meaning depends on its method.
Four Publishers, One Table
Table 1
Sources of Evidence on Hospital-Acquired Conditions
| Publisher | Population | What is counted | Method | Lag | Main blind spot | |
|---|---|---|---|---|---|
| CMS program data | Acute care hospitals paid under Medicare's inpatient system | Each hospital's score on the program's measures and whether it was penalized | Claims-based safety indicators plus infection data reported to CDC | Performance periods end more than a year before the payment year | Hospitals outside the program; conditions not among its measures | |
| CDC National Healthcare Safety Network | Hospitals reporting to the network, nearly all acute care hospitals | Specific infections meeting surveillance definitions | Standardized infection ratios comparing observed with predicted infections | About one year for national reports | Infections not sought or not cultured; non-targeted infections | |
| AHRQ national estimates | National samples of hospital records | A broader set of adverse events, including falls and drug events | Chart review of sampled records | Several years | Hospital-level performance | |
| Peer-reviewed studies | Varies by study | Effects of the program, such as changes after penalties | Claims, registries and statistical designs | Two to five years from data to publication | Generalizing beyond the study's data | |
Compiled for this review; descriptions summarize each source's published methods.
How Each Source Counts
The program's own data are the most directly relevant, since they decide which hospitals are penalized, but they show only what the program measures. A hospital with few catheter infections but many falls would look safe. The claims-based safety indicators depend on how conditions are coded, including whether a condition is flagged as present on admission, so coding practice affects scores.
The CDC network's infection data use standardized definitions applied by trained infection preventionists, which makes them more clinically precise than claims. But surveillance finds only infections that are looked for: a urinary infection never cultured is never counted. The network adjusts for some hospital and patient characteristics through its standardized infection ratio, but not for how often a hospital tests.
National estimates based on chart review cover more kinds of harm and are less dependent on coding, but they cannot rank individual hospitals and arrive years after the care they describe.
Peer-reviewed studies supply the evidence on whether the program works. Sankaran et al. (2019), using a regression discontinuity design on Medicare claims from more than 3,000 hospitals, found no significant shift in hospital-acquired conditions, readmissions or mortality after a first-year penalty. Sheetz et al. (2019), using a Michigan surgical registry, found that targeted conditions declined after the program began, but nontargeted conditions declined more, suggesting the program added little beyond existing trends.
Lag as a Column
Every source trails the care it describes. The program's payment year relies on performance periods that ended more than a year earlier, so a hospital penalized this year is being judged on care delivered two or more years ago. Studies take longer still. No claim in this course should treat a published figure as a description of current performance without stating the period it covers.
Three Contested Questions
Three questions about the evidence remain contested and are described here as debated rather than settled.
First, has care improved? National infection measures have declined over the past decade, but the program began alongside other efforts, including public reporting and national campaigns, so attributing improvement to the penalty is difficult, and the studies above suggest it added little.
Second, does the measure reward looking less hard? Haut and Pronovost (2011) argued that surveillance bias can make hospitals that test more appear worse. The finding that major teaching hospitals, which tend to test and image more, were penalized more often (Rajaram et al., 2015) is consistent with this concern but does not prove it.
Third, how much do coding changes explain? Because the safety indicators come from claims, changes in documentation and present-on-admission coding can move scores without any change in patient harm. No source in the table measures this directly.
Implication
The course's later argument should rely on the program's data for who is penalized, on the CDC network for infection trends, on peer-reviewed studies for effects and on none of them for current performance. Each figure used should carry its source and period. Where two sources disagree, as program scores and chart-review estimates sometimes do, the disagreement itself should be reported, since it usually reflects a difference in what was counted rather than an error in either.
References
Bardach, E., & Patashnik, E. M. (2020). A practical guide for policy analysis: The eightfold path to more effective problem solving (6th ed.). CQ Press.
Haut, E. R., & Pronovost, P. J. (2011). Surveillance bias in outcomes reporting. JAMA, 305(23), 2462-2463. https://doi.org/10.1001/jama.2011.822
Rajaram, R., Chung, J. W., Kinnier, C. V., Barnard, C., Mohanty, S., Pavey, E. S., McHugh, M. C., & Bilimoria, K. Y. (2015). Hospital characteristics associated with penalties in the Centers for Medicare & Medicaid Services Hospital-Acquired Condition Reduction Program. JAMA, 314(4), 375-383. https://doi.org/10.1001/jama.2015.8609
Sankaran, R., Sukul, D., Nuliyalu, U., Gulseren, B., Engler, T. A., Arntson, E., Zlotnick, H., Dimick, J. B., & Ryan, A. M. (2019). Changes in hospital safety following penalties in the US Hospital Acquired Condition Reduction Program: Retrospective cohort study. BMJ, 366, l4109. https://doi.org/10.1136/bmj.l4109
Sheetz, K. H., Dimick, J. B., Englesbe, M. J., & Ryan, A. M. (2019). Hospital-acquired condition reduction program is not associated with additional patient safety improvement. Health Affairs, 38(11), 1858-1865. https://doi.org/10.1377/hlthaff.2018.05504
The Walden MBAX 6332 Week 3 instructions
Week 3 asks you to review the evidence on your policy by examining its sources. Identify the main publishers of data and research, and compare them on the same dimensions: the population covered, what is counted, how, how long the data lag and what each source cannot see. Describe each method in terms of what it can and cannot show. Present the comparison in a table. Then identify the questions on which the evidence is contested, and describe them as debated rather than settled. Close with guidance on which source should be used for which kind of claim later in the course. Expect three to four pages built around a single table.
How this MBAX 6332 Week 3 example is built
A purpose section states the review's rule and cites Bardach and Patashnik. A table compares the program's data, the CDC network, national chart-review estimates and peer-reviewed studies on six columns. A section explains each source's method and limits, including Sankaran and colleagues' finding of no significant change after penalties and Sheetz and colleagues' finding that nontargeted conditions improved more. A lag section warns against treating old data as current. Three contested questions follow, citing Haut and Pronovost and Rajaram and colleagues. A closing section assigns each source to the claims it can support. No figure from any source appears without its period and publisher. Each source's description ends with what it cannot show.
Where the marks sit in the MBAX 6332 Week 3 rubric
Evidence reviews are graded on whether the writer understands how evidence is produced. Comparing sources on identical dimensions earns credit, and the blind-spot column is weighted because it shows critical reading. Methods should be described accurately, including study designs. Recording data lag prevents later misuse and is valued. Contested questions should be described fairly, with evidence on each side, rather than resolved prematurely. Guidance on which source suits which claim shows that the review will be used. A review that lists findings without examining how they were produced, or that presents contested questions as settled, earns fewer marks. Readers should finish knowing which numbers to trust for which purpose.
Common MBAX 6332 Week 3 mistakes, and how to avoid them
List every source of numbers you have seen on your policy, then group them by who publishes them. For each, find out how it counts: claims, surveillance, chart review or a study design. Ask what it would miss, such as conditions never tested for or hospitals outside the program. Note how old its data are. Then list the questions people argue about and the evidence on each side. Keep each description short and neutral. Many reviews jump straight to the findings that support the writer's view. If you need help finding how a dataset was built, send us its name and we can point you to its documentation. Note the years each source covers before quoting it.
Get a MBAX 6332 Week 3 example written to your instructions
Pass along the Week 3 prompt and rubric with the policy and population your brief will address. A custom evidence review arrives within 24-48h, the first free, comparing the agencies and datasets that could supply your figures. No number appears without its publisher, and contested questions are left contested rather than settled in anyone's favor.
More MBAX 6332 papers and MBA samples
- MBAX 6332 Week 1: Health Policy Orientation Post
- MBAX 6332 Week 2: Four-Layer Policy Scan
- MBAX 6332 Week 4: Stakeholder Gains and Burdens
- MBAX 6332 Week 5: Surveillance Bias Policy Brief
- MBAX 6332 Week 6: Policy Recommendation Post
- MBAX 6332 Week 7: Health Policy Equity Analysis
- MBAX 6332 Week 8: Policy Implementation Memo
- MBAX 6332 Week 9: Two-Proposal Analytic Memo
- MBAX 6332 Week 10: Policy Draft Peer Response
- MBAX 6332 Week 11: Final Health Policy Paper
- MBAX 6431 Week 3: Budget Cycle Memo
- MBAX 6007 Week 3: Stock and Flow Map Paper
- MBAX 6005 Week 3: Political Frame Analysis
- WMBA 6882 Week 3: Change Readiness Assessment Memo
MBAX 6332 Week 3 questions, answered
Where can I find a free MBAX 6332 Week 3 sample paper?
The evidence review and its four-source comparison table are posted below, free.
Which sources does the MBAX 6332 Week 3 review compare?
The program's data, the CDC's surveillance network, national chart-review estimates and peer-reviewed studies.
Why include a lag column?
Program data trail the care they describe by more than a year, so no figure should be treated as current.
What does the evidence say about penalties?
A large study found no significant change in conditions, readmissions or deaths after a penalty.
Which questions remain contested?
Whether care improved because of the program, whether the measure rewards testing less and how much coding explains.